

Gino Seravalle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8923034/publications.pdf>

Version: 2024-02-01

188
papers

9,751
citations

41344

49
h-index

39675

94
g-index

190
all docs

190
docs citations

190
times ranked

8115
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure. <i>Clinical Research in Cardiology</i> , 2023, 112, 59-67.	3.3	4
2	Sleep Apnea and Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 23-31.	2.2	15
3	Neuroadrenergic activation in obstructive sleep apnoea syndrome: a new selected meta-analysis - revisited. <i>Journal of Hypertension</i> , 2022, 40, 15-23.	0.5	8
4	Sympathetic nervous system and hypertension: New evidences. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2022, 238, 102954.	2.8	18
5	White-Coat Hypertension Without Organ Damage: Impact on Long-Term Mortality, New Hypertension, and New Organ Damage. <i>Hypertension</i> , 2022, 79, 1057-1066.	2.7	18
6	Heart rate as a predictor of cardiovascular risk. <i>Minerva Medica</i> , 2021, 112, 130-143.	0.9	11
7	Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation. <i>Current Hypertension Reports</i> , 2021, 23, 10.	3.5	16
8	Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction. <i>Hypertension</i> , 2021, 77, 640-649.	2.7	21
9	Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease. <i>Clinical Autonomic Research</i> , 2021, 31, 491-498.	2.5	2
10	Clinical Relevance of the Sympathetic-Vascular Interactions in Health and Disease. <i>Biomedicines</i> , 2021, 9, 1007.	3.2	7
11	Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement. <i>Hypertension</i> , 2021, 78, 1126-1133.	2.7	13
12	Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 408-416.	0.5	25
13	Limited reliability of heart rate as a sympathetic marker in chronic kidney disease. <i>Journal of Hypertension</i> , 2021, 39, 1429-1434.	0.5	3
14	Neuroadrenergic activation in obstructive sleep apnea syndrome: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 2281-2289.	0.5	6
15	Targeting persistent normal left ventricular geometry in the general population: a 25-year follow-up study. <i>Journal of Hypertension</i> , 2021, 39, 952-960.	0.5	2
16	Transient effects of carotid baroreflex stimulation via the neck chamber device on central venous pressure. <i>Journal of Clinical Hypertension</i> , 2021, , .	2.0	1
17	Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload. <i>Hypertension</i> , 2020, 76, 1444-1450.	2.7	16
18	Sympathomodulation in congestive heart failure: From drugs to devices. <i>International Journal of Cardiology</i> , 2020, 321, 118-125.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020, 38, 1436-1442.	0.5	26
20	Assessment of heart rate as a sympathetic biomarker™: strengths and pitfalls. <i>Journal of Hypertension</i> , 2020, 38, 1460-1461.	0.5	2
21	Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies. <i>Journal of Hypertension</i> , 2020, 38, 565-572.	0.5	20
22	Heart rate as cardiovascular risk factor. <i>Postgraduate Medicine</i> , 2020, 132, 358-367.	2.0	11
23	Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. <i>Hypertension</i> , 2020, 76, 577-582.	2.7	33
24	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2027.	2.4	12
25	Microvascular Alterations in Obesity. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 137-147.	0.1	0
26	Secondary Hypertension and Cardiovascular Risk: An Overview. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 197-209.	0.1	1
27	Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. <i>Hypertension</i> , 2019, 74, 903-909.	2.7	13
28	Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings. <i>Current Hypertension Reports</i> , 2019, 21, 90.	3.5	1
29	Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. <i>Journal of Hypertension</i> , 2019, 37, 443-448.	0.5	47
30	Sympathetic Neural Overdrive in the Obese and Overweight State. <i>Hypertension</i> , 2019, 74, 349-358.	2.7	87
31	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. <i>Cardiovascular Research</i> , 2019, 116, 429-437.	3.8	20
32	Neural Mechanisms. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 71-86.	0.1	0
33	Sympathetic neural overdrive in congestive heart failure and its correlates. <i>Journal of Hypertension</i> , 2019, 37, 1746-1756.	0.5	34
34	Baroreflex activation therapy systems: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2019, 16, 1025-1033.	2.8	14
35	The Role of the Brain in Neurogenic Prehypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 349-360.	0.1	0
36	Age- and Sex-Specific Reference Values for Media/Lumen Ratio in Small Arteries and Relationship With Risk Factors. <i>Hypertension</i> , 2018, 71, 1193-1200.	2.7	22

#	ARTICLE	IF	CITATIONS
37	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1427-1440.	0.5	86
38	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1441-1455.	0.5	44
39	Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state. Journal of Hypertension, 2018, 36, 1195-1200.	0.5	6
40	Baroreceptor Stimulation. , 2018, , 1323-1327.		1
41	Sympathetic Nervous System, Sleep, and Hypertension. Current Hypertension Reports, 2018, 20, 74.	3.5	45
42	The Sympathetic Nervous System in Hypertension. Contemporary Endocrinology, 2018, , 201-212.	0.1	2
43	Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. Hypertension, 2018, 72, 483-491.	2.7	79
44	Neurogenic Hypertension. , 2018, , 381-382.		0
45	Treatment of Resistant Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 639-652.	0.1	0
46	Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 289-296.	2.2	2
47	Obesity and hypertension. Pharmacological Research, 2017, 122, 1-7.	7.1	430
48	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. Journal of Hypertension, 2017, 35, 2532-2536.	0.5	28
49	Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. Nephrology Dialysis Transplantation, 2017, 32, 1351-1356.	0.7	16
50	Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. Journal of Hypertension, 2017, 35, 1685-1690.	0.5	16
51	Lercanidipine in the management of hypertension: An update. Journal of Pharmacology and Pharmacotherapeutics, 2017, 8, 155.	0.4	24
52	Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. Clinical Research in Cardiology, 2016, 105, 838-846.	3.3	22
53	Effects of Renal Denervation on Sympathetic Nervous System Activity. Updates in Hypertension and Cardiovascular Protection, 2016, , 303-319.	0.1	0
54	Do Combined Electrocardiographic and Echocardiographic Markers of Left Ventricular Hypertrophy Improve Cardiovascular Risk Estimation?. Journal of Clinical Hypertension, 2016, 18, 846-854.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. <i>Advances in Therapy</i> , 2016, 33, 2173-2187.	2.9	7
56	[OP.4B.08] PROGNOSTIC RELEVANCE OF ELECTROCARDIOGRAPHIC TP-TE INTERVAL IN THE GENERAL AND IN THE HYPERTENSIVE POPULATION. <i>Journal of Hypertension</i> , 2016, 34, e46.	0.5	0
57	[OP.6B.06] EVALUATION OF RELATIONSHIP BETWEEN CARDIO-ANKLE VASCULAR INDEX AND 24H AMBULATORY BLOOD PRESSURE VARIABLES. <i>Journal of Hypertension</i> , 2016, 34, e70.	0.5	0
58	Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights. <i>Current Hypertension Reports</i> , 2016, 18, 60.	3.5	7
59	Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study. <i>European Heart Journal</i> , 2016, 37, 988-995.	2.2	10
60	Differential effects of enalapril+felodipine versus enalapril+lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 244-251.	2.3	9
61	Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 175-179.	2.2	73
62	Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1367-1375.	3.4	140
63	Within-visit BP variability, cardiovascular risk factors, and BP control in central and eastern Europe. <i>Journal of Hypertension</i> , 2015, 33, 2250-2256.	0.5	14
64	9C.07. <i>Journal of Hypertension</i> , 2015, 33, e124-e125.	0.5	1
65	Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states. <i>Journal of Hypertension</i> , 2015, 33, 1411-1417.	0.5	61
66	Long-term chronic baroreflex activation. <i>Journal of Hypertension</i> , 2015, 33, 1704-1708.	0.5	42
67	8B.02. <i>Journal of Hypertension</i> , 2015, 33, e107.	0.5	0
68	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1560-1567.	4.5	11
69	HYT-Hypertension in Turkey: A Cross-Sectional Survey on Blood Pressure Control with Calcium Channel Blockers Alone or Combined with Other Antihypertensive Drugs. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 165-172.	2.2	7
70	Carotid Baroreceptor Stimulation in Resistant Hypertension and Heart Failure. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 233-239.	2.2	1
71	Blood Pressure Responses to Renal Denervation Precede and Are Independent of the Sympathetic and Baroreflex Effects. <i>Hypertension</i> , 2015, 65, 1209-1216.	2.7	65
72	Role of Sympathetic Nervous System in the Metabolic Syndrome and Sleep Apnea. , 2015, , 165-175.		1

#	ARTICLE	IF	CITATIONS
73	Neurogenic and Non-neurogenic Mechanisms of White-Coat Hypertension. , 2015, , 51-60.		0
74	Neurohormonal Interactions. , 2015, , 137-150.		1
75	Arterial Alterations in Hypertension. , 2015, , 285-297.		0
76	Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 63-68.	1.7	8
77	Long-Term Sympathoinhibitory Effects of Surgically Induced Weight Loss in Severe Obese Patients. Hypertension, 2014, 64, 431-437.	2.7	62
78	Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. International Journal of Cardiology, 2014, 177, 1020-1025.	1.7	93
79	Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. European Journal of Heart Failure, 2014, 16, 977-983.	7.1	152
80	Evaluation of microvascular structure in humans. Journal of Hypertension, 2014, 32, 2120-2129.	0.5	53
81	Role of the Sympathetic Nervous System in Hypertension and Hypertension-Related Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 89-105.	2.2	40
82	Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. Journal of Hypertension, 2014, 32, 383-388.	0.5	22
83	Role of Ambulatory Blood Pressure Monitoring in Resistant Hypertension. Current Hypertension Reports, 2013, 15, 232-237.	3.5	22
84	Failure of monolateral renal nerve ablation to exert sympathoinhibitory and blood pressure lowering effects in a patient with resistant hypertension: A case report. International Journal of Cardiology, 2013, 169, e120-e121.	1.7	4
85	Differential patterns of regional neuroadrenergic cardiovascular drive in acromegalic disease. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 333-337.	1.9	2
86	Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. Journal of Hypertension, 2013, 31, 2018-2024.	0.5	58
87	Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement. Journal of Hypertension, 2013, 31, 1131-1135.	0.5	26
88	Structural Alterations of the Retinal Microcirculation in the "Prehypertensive" High-Normal Blood Pressure State. Current Pharmaceutical Design, 2013, 19, 2375-2381.	1.9	19
89	How to Assess Sympathetic Nervous System Activity in Clinical Practice. Current Clinical Pharmacology, 2013, 8, 182-188.	0.6	16
90	Home and ambulatory blood pressure in resistant hypertension. EuroIntervention, 2013, 9, R35-R41.	3.2	5

#	ARTICLE	IF	CITATIONS
91	The Role of Carotid Baroreceptor Stimulation. , 2013, , 137-144.		0
92	Sympathetic regulation of vascular function in health and disease. <i>Frontiers in Physiology</i> , 2012, 3, 284.	2.8	174
93	Sympathetic nervous system. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 46-51.	2.0	102
94	The "Sympathetic" Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation. <i>Current Hypertension Reviews</i> , 2012, 8, 250-255.	0.9	0
95	The Sympathetic Nervous System and New Nonpharmacologic Approaches to Treating Hypertension: A Focus on Renal Denervation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 311-317.	1.7	25
96	Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation. <i>Current Hypertension Reports</i> , 2012, 14, 567-572.	3.5	10
97	Decreased adrenergic tone in acromegaly: evidence from direct recording of muscle sympathetic nerve activity. <i>Clinical Endocrinology</i> , 2012, 77, 262-267.	2.4	9
98	Sympatho-Vagal Imbalance in Hypertension. , 2012, , 345-348.		3
99	Blood Pressure Control and Antihypertensive Treatment. <i>Current Vascular Pharmacology</i> , 2012, 10, 506-511.	1.7	5
100	The "Sympathetic" Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation. <i>Current Hypertension Reviews</i> , 2012, 8, 250-255.	0.9	0
101	The new concept of total cardiovascular risk management. <i>Italian Journal of Medicine</i> , 2011, 5, 169-174.	0.3	0
102	Sympathoinhibitory effects of statins in chronic kidney disease. <i>Journal of Hypertension</i> , 2011, 29, 2064-2067.	0.5	3
103	Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population. <i>Journal of Hypertension</i> , 2011, 29, 1121-1127.	0.5	18
104	Sympathetic Mechanisms, Organ Damage, and Antihypertensive Treatment. <i>Current Hypertension Reports</i> , 2011, 13, 303-308.	3.5	44
105	Cardiovascular consequences of poor compliance to antihypertensive therapy. <i>Blood Pressure</i> , 2011, 20, 196-203.	1.5	11
106	Diagnosis and management of patients with white-coat and masked hypertension. <i>Nature Reviews Cardiology</i> , 2011, 8, 686-693.	13.7	75
107	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2620-2627.	4.5	46
108	Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure. <i>Hypertension</i> , 2011, 57, 846-851.	2.7	268

#	ARTICLE	IF	CITATIONS
109	Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease. <i>Current Hypertension Reviews</i> , 2011, 7, 60-65.	0.9	0
110	Impact of the metabolic syndrome on subcutaneous microcirculation in obese patients. <i>Journal of Hypertension</i> , 2010, 28, 1708-1714.	0.5	30
111	Structural and Functional Alterations of Subcutaneous Small Resistance Arteries in Severe Human Obesity. <i>Obesity</i> , 2010, 18, 92-98.	3.0	98
112	The "neuroadrenergic hypothesis"™ in hypertension: current evidence. <i>Experimental Physiology</i> , 2010, 95, 581-586.	2.0	135
113	Sympathetic Activation in Obesity. <i>Hypertension</i> , 2010, 56, 338-340.	2.7	21
114	Diurnal blood pressure variation and sympathetic activity. <i>Hypertension Research</i> , 2010, 33, 381-385.	2.7	89
115	Blood pressure control in resistant hypertension: new therapeutic options. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1579-1585.	1.5	8
116	Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea. <i>Journal of Hypertension</i> , 2010, 28, 1313-1320.	0.5	41
117	Sympathetic and Baroreflex Cardiovascular Control in Hypertension-Related Left Ventricular Dysfunction. <i>Hypertension</i> , 2009, 53, 205-209.	2.7	157
118	Response to Possible Difference in the Sympathetic Activation on Extreme Dippers With or Without Exaggerated Morning Surge. <i>Hypertension</i> , 2009, 53, .	2.7	0
119	Heart Rate, Sympathetic Cardiovascular Influences, and The Metabolic Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 31-37.	3.1	69
120	Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 469-475.	2.6	19
121	Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1446-1451.	3.4	19
122	Metabolic syndrome and cardiometabolic risk: An update. <i>Blood Pressure</i> , 2009, 18, 7-16.	1.5	15
123	Protective effects of renin-angiotensin blockade beyond blood pressure control. <i>Journal of Human Hypertension</i> , 2009, 23, 570-577.	2.2	10
124	Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. <i>Journal of Hypertension</i> , 2009, 27, 562-566.	0.5	24
125	Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications. <i>Current Vascular Pharmacology</i> , 2009, 7, 137-145.	1.7	36
126	Blood Pressure Lowering Effects of Rimonabant in Obesity-related Hypertension. <i>Journal of Neuroendocrinology</i> , 2008, 20, 63-68.	2.6	13

#	ARTICLE	IF	CITATIONS
127	10.1 Sympathetic Responses to Ventricular Extrasystolic Beats in Obese Subjects without and with Sleep Apnoea. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 290-290.	2.2	0
128	Adrenergic, Metabolic, and Reflex Abnormalities in Reverse and Extreme Dipper Hypertensives. Hypertension, 2008, 52, 925-931.	2.7	178
129	Heart rate as a sympathetic marker during acute adrenergic challenge. Journal of Hypertension, 2008, 26, 70-75.	0.5	14
130	Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique. Journal of Hypertension, 2008, 26, 2185-2190.	0.5	6
131	Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic Syndrome. Hypertension, 2007, 49, 535-541.	2.7	117
132	Response to Sympathetic Activity, Heart Failure, Obesity, and Metabolic Syndrome: Is There Any Role for Sleep Apnea?. Hypertension, 2007, 49, .	2.7	0
133	Neurogenic Abnormalities in Masked Hypertension. Hypertension, 2007, 50, 537-542.	2.7	121
134	Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 473-481.	2.6	58
135	Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Pressure, 2006, 15, 268-274.	1.5	6
136	Baroreflex Function in Hypertension: Consequences for Antihypertensive Therapy. Progress in Cardiovascular Diseases, 2006, 48, 407-415.	3.1	46
137	Autonomic imbalance and metabolic syndrome: unravelling interactions, mechanisms and outcomes. Journal of Hypertension, 2006, 24, 47-49.	0.5	24
138	Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia, 2005, 48, 1359-1365.	6.3	259
139	Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. Journal of Hypertension, 2004, 22, 1747-1753.	0.5	28
140	Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiologica Scandinavica, 2003, 177, 399-404.	2.2	37
141	Tolerability and treatment compliance with angiotensin II receptor antagonists. American Journal of Hypertension, 2003, 16, 1066-1073.	2.0	49
142	Impairment of Thermoregulatory Control of Skin Sympathetic Nerve Traffic in the Elderly. Circulation, 2003, 108, 729-735.	1.6	80
143	Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension. Hypertension, 2003, 41, 558-562.	2.7	54
144	Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients. Hypertension, 2003, 42, 873-877.	2.7	95

#	ARTICLE	IF	CITATIONS
145	Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals. <i>Journal of Hypertension</i> , 2003, 21, 1761-1769.	0.5	202
146	Sympathetic Response to Ventricular Extrasystolic Beats in Hypertension and Heart Failure. <i>Hypertension</i> , 2002, 39, 886-891.	2.7	28
147	Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension. <i>Circulation</i> , 2002, 106, 1957-1961.	1.6	126
148	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141-146.	4.3	45
149	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141.	4.3	15
150	Participation of the Hypothalamus-Hypophysis Axis in the Sympathetic Activation of Human Obesity. <i>Hypertension</i> , 2001, 38, 1316-1320.	2.7	56
151	Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure. <i>Hypertension</i> , 2001, 38, 286-291.	2.7	31
152	Effects of Cigarette Smoking on Systemic Hemodynamics. , 2000, 130, 21-30.		5
153	Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. <i>Journal of Hypertension</i> , 2000, 18, 587-593.	0.5	83
154	Adrenergic and Reflex Abnormalities in Obesity-Related Hypertension. <i>Hypertension</i> , 2000, 36, 538-542.	2.7	259
155	Sympathoexcitatory responses to the acute blood pressure fall induced by central or peripheral antihypertensive drugs. <i>American Journal of Hypertension</i> , 2000, 13, 29-34.	2.0	23
156	Sympathetic Nerve Traffic Responses to Surgical Removal of Pheochromocytoma. <i>Hypertension</i> , 1999, 34, 461-465.	2.7	38
157	Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. <i>Hypertension</i> , 1999, 33, 671-675.	2.7	19
158	Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 84, 525-529.	1.6	20
159	Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage. <i>Hypertension</i> , 1999, 34, 724-728.	2.7	428
160	Dissociation Between Muscle and Skin Sympathetic Nerve Activity in Essential Hypertension, Obesity, and Congestive Heart Failure. <i>Hypertension</i> , 1998, 31, 64-67.	2.7	228
161	Baroreflex Control of Sympathetic Nerve Activity in Essential and Secondary Hypertension. <i>Hypertension</i> , 1998, 31, 68-72.	2.7	443
162	Body Weight Reduction, Sympathetic Nerve Traffic, and Arterial Baroreflex in Obese Normotensive Humans. <i>Circulation</i> , 1998, 97, 2037-2042.	1.6	321

#	ARTICLE	IF	CITATIONS
163	Heart rate as marker of sympathetic activity. <i>Journal of Hypertension</i> , 1998, 16, 1635-1639.	0.5	231
164	Comparison between Reproducibility and Sensitivity of Muscle Sympathetic Nerve Traffic and Plasma Noradrenaline in Man. <i>Clinical Science</i> , 1997, 92, 285-289.	4.3	114
165	Left Ventricular Hypertrophy and Sympathetic Activity. <i>Advances in Experimental Medicine and Biology</i> , 1997, 432, 173-179.	1.6	9
166	Effects of Chronic ACE Inhibition on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. <i>Circulation</i> , 1997, 96, 1173-1179.	1.6	173
167	Baroreflex Impairment by Low Sodium Diet in Mild or Moderate Essential Hypertension. <i>Hypertension</i> , 1997, 29, 802-807.	2.7	51
168	Benefit versus risk of calcium antagonists in hypertensive patients with concomitant risk factors. <i>Journal of Hypertension</i> , 1996, 14, S33-S34.	0.5	4
169	Sympathetic Activation and Loss of Reflex Sympathetic Control in Mild Congestive Heart Failure. <i>Circulation</i> , 1995, 92, 3206-3211.	1.6	351
170	Sympathetic Activation in Obese Normotensive Subjects. <i>Hypertension</i> , 1995, 25, 560-563.	2.7	472
171	Mechanisms responsible for sympathetic activation by cigarette smoking in humans.. <i>Circulation</i> , 1994, 90, 248-253.	1.6	347
172	Physical training and baroreceptor control of sympathetic nerve activity in humans.. <i>Hypertension</i> , 1994, 23, 294-301.	2.7	151
173	Short-and long-term reproducibility of techniques employed to assess sympathetic tone in humans. <i>Journal of Hypertension</i> , 1993, 11, S166-S167.	0.5	2
174	Cigarette Smoking and the Adrenergic Nervous System. <i>Clinical and Experimental Hypertension</i> , 1992, 14, 251-260.	0.3	29
175	Sympathomoderating influence of benazepril in essential hypertension. <i>Journal of Hypertension</i> , 1992, 10, 373-378.	0.5	24
176	Effect of Oral Dilevalol on Forearm Circulation in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1992, 19, 367-370.	1.9	1
177	Physical Exercise in Essential Hypertension. <i>Chest</i> , 1992, 101, 312S-314S.	0.8	36
178	Effect of detraining on the cardiopulmonary reflex in professional runners and hammer throwers. <i>American Journal of Cardiology</i> , 1992, 69, 677-680.	1.6	12
179	Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 69, 873-878.	1.6	20
180	Reflex cardiovascular control in congestive heart failure. <i>American Journal of Cardiology</i> , 1992, 69, 17-23.	1.6	54

#	ARTICLE	IF	CITATIONS
181	Left ventricular hypertrophy and the ??cardiogenic reflex?? in man. Journal of Hypertension, 1991, 9, S43-S50.	0.5	10
182	Early alterations of the baroreceptor control of heart rate in patients with acute myocardial infarction.. Circulation, 1990, 81, 939-948.	1.6	94
183	Cardiopulmonary receptor reflexes in normotensive athletes with cardiac hypertrophy.. Circulation, 1990, 82, 1222-1229.	1.6	30
184	Alterations of the Cardiopulmonary Reflex with Hypertension and Aging in Man. Clinical and Experimental Hypertension, 1989, 11, 199-210.	0.3	1
185	Effects of dilevalol on forearm circulation in essential hypertension. American Journal of Cardiology, 1989, 63, 121-124.	1.6	3
186	Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. American Heart Journal, 1989, 117, 740-745.	2.7	19
187	Cardiac hypertrophy impairs cardiac receptor control of circulation in man. Journal of Hypertension, 1989, 7, S56-57.	0.5	4
188	Effects of ageing on the cardiopulmonary receptor reflex in normotensive humans. Journal of Hypertension, 1988, 6, S141-144.	0.5	14